Mark H.H. Kramer

9.0k total citations · 3 hit papers
154 papers, 5.8k citations indexed

About

Mark H.H. Kramer is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Mark H.H. Kramer has authored 154 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Endocrinology, Diabetes and Metabolism, 31 papers in Surgery and 24 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Mark H.H. Kramer's work include Diabetes Treatment and Management (42 papers), Diabetes Management and Research (21 papers) and Pancreatic function and diabetes (17 papers). Mark H.H. Kramer is often cited by papers focused on Diabetes Treatment and Management (42 papers), Diabetes Management and Research (21 papers) and Pancreatic function and diabetes (17 papers). Mark H.H. Kramer collaborates with scholars based in Netherlands, United States and Vietnam. Mark H.H. Kramer's co-authors include Daniël H. van Raalte, Mark M. Smits, Marcel H.A. Muskiet, Lennart Tonneijck, Michaëla Diamant, Prabath W.B. Nanayakkara, Jaap A. Joles, Max Nieuwdorp, Trynke Hoekstra and Erik H. Serné and has published in prestigious journals such as Blood, Journal of the American College of Cardiology and PLoS ONE.

In The Last Decade

Mark H.H. Kramer

151 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

2017 294 citations Marcel H.A. Muskiet, Lennart Tonneijck et al. profile →
Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial

2016 289 citations C.A.J. van Beers, Mark M. Smits et al. profile →
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

2019 253 citations Erik J.M. van Bommel, Marcel H.A. Muskiet et al. Kidney International profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark H.H. Kramer Netherlands	42	2.1k	1.5k	840	787	751	154	5.8k
Nicolas Rodondi Switzerland	54	3.5k 1.7×	1.7k 1.1×	1.2k 1.5×	1.2k 1.6×	896 1.2×	397	10.7k
Inger Njølstad Norway	52	1.3k 0.6×	1.3k 0.9×	1.2k 1.4×	1.0k 1.3×	761 1.0×	214	9.8k
José Carlos Nicolau Brazil	46	1.4k 0.7×	2.7k 1.8×	717 0.9×	957 1.2×	917 1.2×	339	9.3k
John Goudevenos Greece	38	723 0.3×	1.6k 1.1×	677 0.8×	619 0.8×	556 0.7×	194	6.3k
Dongjie Fan United States	18	1.1k 0.5×	1.8k 1.2×	1.1k 1.4×	466 0.6×	1.1k 1.5×	38	11.1k
Meg Jardine Australia	46	3.1k 1.5×	1.8k 1.2×	646 0.8×	363 0.5×	1.0k 1.4×	216	7.6k
Hideki Origasa Japan	47	2.1k 1.0×	2.3k 1.5×	1.2k 1.4×	762 1.0×	828 1.1×	254	9.6k
Adrian Covic Romania	55	772 0.4×	2.1k 1.4×	889 1.1×	819 1.0×	724 1.0×	314	9.4k
Charlotte Andersson Denmark	45	906 0.4×	1.3k 0.8×	921 1.1×	471 0.6×	810 1.1×	201	7.2k
Eleanor Danielson United States	10	2.2k 1.1×	5.6k 3.8×	1.9k 2.3×	510 0.6×	983 1.3×	16	10.0k

Countries citing papers authored by Mark H.H. Kramer

Since Specialization

Citations

This map shows the geographic impact of Mark H.H. Kramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark H.H. Kramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark H.H. Kramer more than expected).

Fields of papers citing papers by Mark H.H. Kramer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark H.H. Kramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark H.H. Kramer. The network helps show where Mark H.H. Kramer may publish in the future.

Co-authorship network of co-authors of Mark H.H. Kramer

This figure shows the co-authorship network connecting the top 25 collaborators of Mark H.H. Kramer. A scholar is included among the top collaborators of Mark H.H. Kramer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark H.H. Kramer. Mark H.H. Kramer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dam, Rob M. van, Dorret I. Boomsma, Linde van Lee, et al.. (2024). Development of a Diabetes Dietary Quality Index: Reproducibility and Associations with Measures of Insulin Resistance, Beta Cell Function, and Hyperglycemia. Nutrients. 16(20). 3512–3512. 1 indexed citations

Ruiten, Charlotte C. van, Dick J. Veltman, Anouk Schrantee, et al.. (2022). Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 107(6). e2590–e2599. 12 indexed citations

Schinkel, Michiel, Eva S. van den Ende, Paul Elbers, et al.. (2022). Using machine learning to predict blood culture outcomes in the emergency department: a single-centre, retrospective, observational study. BMJ Open. 12(1). e053332–e053332. 12 indexed citations

Velzen, Daan van, Mark M. Smits, Erik J.M. van Bommel, et al.. (2021). Kidney hemodynamic function in men and postmenopausal women with type 2 diabetes and preserved kidney function. American Journal of Physiology-Renal Physiology. 320(6). F1152–F1158. 2 indexed citations

Muskiet, Marcel H.A., Lennart Tonneijck, Mark M. Smits, et al.. (2021). Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes ( RENALIS ): A predefined substudy of a randomized, double‐blind trial. Diabetes Obesity and Metabolism. 24(1). 115–124. 6 indexed citations

Smits, Mark M., Hilde Herrema, Mark Davids, et al.. (2021). Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes. Diabetes & Metabolism. 47(5). 101223–101223. 48 indexed citations

Kraaijenhof, Jordan M, Marcel H.A. Muskiet, Lennart Tonneijck, et al.. (2020). Effects of dipeptidyl peptidase‐4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8‐week, randomized, controlled, double‐blind trial. Diabetes Obesity and Metabolism. 22(10). 1847–1856. 7 indexed citations

Emanuel, Anna L., Rick I. Meijer, Daniël H. van Raalte, et al.. (2020). Effects of a Hypercaloric and Hypocaloric Diet on Insulin-Induced Microvascular Recruitment, Glucose Uptake, and Lipolysis in Healthy Lean Men. Arteriosclerosis Thrombosis and Vascular Biology. 40(7). 1695–1704. 7 indexed citations

Bommel, Erik J.M. van, Frank Geurts, Marcel H.A. Muskiet, et al.. (2020). SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid–base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes. Clinical Science. 134(23). 3107–3118. 24 indexed citations

10.

Bommel, Erik J.M. van, Marcel H.A. Muskiet, Michaël J.B. van Baar, et al.. (2019). The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney International. 97(1). 202–212. 253 indexed citations breakdown →

11.

Rombach, Saskia M., et al.. (2018). Results on patient flow of implementing an Acute Medical Unit.. PubMed. 17(2). 62–67. 3 indexed citations

12.

Emanuel, Anna L., Nicolien C. de Clercq, Annefleur M. Koopen, et al.. (2018). Iloprost infusion prevents the insulin‐induced reduction in skeletal muscle microvascular blood volume but does not enhance peripheral glucose uptake in type 2 diabetic patients. Diabetes Obesity and Metabolism. 20(11). 2523–2531. 7 indexed citations

13.

Tonneijck, Lennart, Marcel H.A. Muskiet, Mark M. Smits, et al.. (2018). Effect of immediate and prolonged GLP‐1 receptor agonist administration on uric acid and kidney clearance: Post‐hoc analyses of four clinical trials. Diabetes Obesity and Metabolism. 20(5). 1235–1245. 30 indexed citations

14.

Beers, C.A.J. van, Maartje de Wit, Wilmy Cleijne, et al.. (2017). Keeping safe. Continuous glucose monitoring (CGM) in persons with Type 1 diabetes and impaired awareness of hypoglycaemia: a qualitative study. Diabetic Medicine. 34(10). 1470–1476. 30 indexed citations

15.

Emanuel, Anna L., Erica S. Klaassen, Ajay Verma, et al.. (2017). Relationships Between Type 2 Diabetes, Neuropathy, and Microvascular Dysfunction: Evidence From Patients With Cryptogenic Axonal Polyneuropathy. Diabetes Care. 40(4). 583–590. 15 indexed citations

16.

Tonneijck, Lennart, Marcel H.A. Muskiet, Mark M. Smits, et al.. (2017). Postprandial renal haemodynamic effect of lixisenatide vs once‐daily insulin‐glulisine in patients with type 2 diabetes on insulin‐glargine: An 8‐week, randomised, open‐label trial. Diabetes Obesity and Metabolism. 19(12). 1669–1680. 55 indexed citations

17.

Galen, Louise S. van, Tim Cooksley, Hanneke Merten, et al.. (2016). Physician consensus on preventability and predictability of readmissions based on standard case scenarios.. PubMed. 74(10). 434–442. 5 indexed citations

18.

Galen, Louise S. van, et al.. (2016). A Protocolised Once a Day Modified Early Warning Score (MEWS) Measurement Is an Appropriate Screening Tool for Major Adverse Events in a General Hospital Population. PLoS ONE. 11(8). e0160811–e0160811. 39 indexed citations

19.

Alam, Nadia, et al.. (2015). Exploring the performance of the National Early Warning Score (NEWS) in a European emergency department. Resuscitation. 90. 111–115. 129 indexed citations

20.

Smits, Mark M., Lennart Tonneijck, Marcel H.A. Muskiet, et al.. (2015). Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. BMJ Open. 5(11). e009579–e009579. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact